NCT07910383Recruiting
The Use of Contrast Enhanced Ultrasound (CEUS) In Post-Surgical Pancreatic Cancer Patients to Evaluate Local Disease Recurrence
The Use of Contrast Enhanced Ultrasound (CEUS) In Post-Surgical Pancreatic Cancer Patients to Evaluate Local Disease Recurrence- A Feasibility Study
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
This pilot study is testing whether a special type of ultrasound called contrast-enhanced ultrasound (CEUS) can help detect if pancreatic cancer has come back after surgery. People may be eligible to participate if they had surgery to remove pancreatic ductal adenocarcinoma (PDAC) from the head or body of the pancreas and are currently being monitored for cancer recurrence using CT scans. The study plans to enroll 10 participants: 5 people whose cancer has returned and 5 people whose cancer has not returned, based on their standard medical imaging results. Participants will not be randomly assigned to groups. Researchers will use a Logiq E10 ultrasound machine with CEUS technology to perform an ultrasound examination of the area where the surgery was performed. The goal is to determine whether CEUS can be a practical and useful tool for identifying local pancreatic cancer recurrence.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 26 Oct 2026
- Start date
- 29 Jul 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Thomas Jefferson University
- Diseases
- Pancreatic cancer
- NCT number
- NCT07910383
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 29 Jul 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Females who are pregnant or nursing.
- Patients who have received an investigational drug in the 30 days before study drug administration or will receive one within 72 hours afterwards.
- Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:
- Patients on life support or in a critical care unit.
- Patients with clinically unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias)
- Patients with recent cerebral hemorrhage (within 1 month).
- Patients who have undergone surgery within 24 hours prior to the study ultrasound imaging examination.
- Patients with congenital heart defects.
- Patient with a known allergy to Lumason.
Who the study is looking for
- Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:
- Be a patient that underwent surgical resection of PDAC located in the head or body of the pancreas and are being followed for recurrence with CT imaging as part of their standard of care.
- Be 18 years of age or older.
- If the subject is of child-bearing potential, must have a negative pregnancy test.
- Be conscious and able to comply with study procedures.
- Have read and signed the IRB approved consent form for participating in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.